Skip to main content
Fig. 1 | BMC Infectious Diseases

Fig. 1

From: Impact of GeneXpert MTB/RIF® on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia

Fig. 1

Participant flow chart. * 53/58 RIF-resistant patients were included in Kaplan-Meier and Cox Proportional Hazard analysis (28 from pre- and 25 from post-Xpert group); 5/30 RIF-resistant patients from Post-Xpert group did not have dates of SLD treatment initiation; ** 305 patients were included in treatment outcome analysis (252 RIF-susceptible and 53 RIF-resistant patients)

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us